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In uncomplicated pregnancies, first trimester androgen, oestrogen and prolactin concentrations were higher in nulliparous (n¼160)
than parous (n¼260) mothers. Androgens and estrogens were higher in younger than older mothers. These data are consistent with
elevated hormone concentrations mediating the breast cancer protection from a first pregnancy and pregnancies occurring at
younger ages.
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There are few opportunities to directly evaluate the hypothesis that
the pregnancy hormonal milieu influences cancer risk in the
mother and offspring. Investigations have instead used proxies to
reflect the endocrine environment such as birth weight which is
associated with a modestly elevated breast cancer risk in the
daughter (Michels and Xue, 2006). Whereas age at first and last
pregnancy and parity are established maternal breast cancer risk
factors (National Cancer Institute, 2003), associations have been
less consistent for other pregnancy characteristics with regard to
the mother (Cnattingius et al, 2005) and offspring (Potischman
et al, 2004).
The few studies on hormone variations by maternal and
pregnancy characteristics have focused on maternal measures in
mid- or late pregnancy, primarily estrogens. Because the timing of
carcinogenic events is unknown, characterising hormones over the
entire pregnancy may provide additional insights into the
biological mechanisms for maternal and perinatal breast cancer
risk factors.
MATERIALS AND METHODS
Data derived from an obstetrical study at the Massachusetts
General Hospital (MGH) in Boston, Massachusetts that began in
1998 (Thadhani et al, 2001). Women were recruited at their first
prenatal visit (ranging from 6.4 to 19.9 weeks gestation (median
11) with over 90% in the first 13 weeks), interviewed, and asked to
provide a blood sample. Participants gave informed consent and
the study was approved by the MGH Institutional Review Board.
The study sample, described previously (Potischman et al,
2005), includes 109 Hispanic, 56 African American and 255
Caucasian women 18–42 years of age (median 29.6), who delivered
a live, singleton birth in an uncomplicated pregnancy. A total of
38% of the women were nulliparous.
Laboratory assays
Sample handling, storage and assays were described previously
(Potischman et al, 2005). Intra-class correlation coefficients from
repeated measures of blind quality control samples were 97% for
oestradiol, 92% for SHBG, 90% for oestrone, 85% for androste-
nedione, 76% for prolactin, 76% for testosterone, 60% for
progesterone and o50% for DHEAS. Hormone medians and
ranges have been published (Potischman et al, 2005).
Statistical methods
Spearman correlation coefficients were calculated using contin-
uous data. All pregnancy factors associated with the hormones in
unadjusted analyses were entered with gestational age at blood
collection (excluding pregnancies with 14þ weeks’ gestation) into
linear regression models with logarithm-transformed hormones as
dependent variables. Exponentiated b estimates ( 1.0) from these
models are presented for factors which remained significantly
associated with the hormones, or changed o10% from the
unadjusted models. Interactions between maternal age (o30,
30þ years) and parity (nulliparous, parous) were tested by
including the main effects and cross-product terms in a regression
model. Additional interactions between all pregnancy factors and
hormones by offspring sex and race were evaluated. Statistical
significance was defined as Po0.05.
RESULTS
Gestational age at blood collection was inversely correlated with
the androgens and positively correlated with the estrogens,
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yprogesterone, prolactin and SHBG (Table 1). Correlations with first
trimester hormones were demonstrated for maternal age, weight
and BMI, but not maternal height or birth weight.
In analyses mutually adjusted for the pregnancy factors and
including gestational age, androgen and oestrogen concentrations
were lower in older mothers (Table 2); the greatest incremental
difference was between those o30 and 30þ years (e.g., Po0.001
for androstenedione; other data not shown). In contrast, maternal
age was positively associated with progesterone. The androgens,
estrogens and prolactin were higher in the 160 nulliparous than in
the 260 parous women. Maternal BMI (and maternal weight; data
not shown) was positively associated with the androgens and
inversely associated with progesterone and SHBG, and maternal
height was inversely associated with the estrogens and SHBG
though not with the other hormones. Current smokers had lower
progesterone and prolactin concentrations, whereas alcohol users
had lower oestradiol only.
The positive association of maternal BMI and androstenedione
was limited to mothers of female fetuses (P¼0.01); there were no
other interactions by offspring sex. Differences in hormones by
race/ethnicity were reported in an earlier paper from this study
(Potischman et al, 2005). The associations between the pregnancy
factors and hormones were similar with adjustment for race/
ethnicity and there were no meaningful interactions demonstrated
(data not shown).
Except for progesterone, the highest hormone concentrations
were generally observed in nulliparous women less than age 30
years and the lowest concentrations in parous women age 30 years
and over although none of the interactions were significant
(P ranged from 0.36 for SHBG to 0.79 for prolactin). In contrast,
nulliparous women age 30þ years had higher progesterone
concentrations than younger nulliparous women or parous women
of any age (P for interaction¼0.006).
DISCUSSION
There are few previous data characterising hormone variations in
the first trimester. Our results for first compared with subsequent
full-term pregnancies confirm previous findings of higher
oestradiol (Bernstein et al, 1986), while also demonstrating
elevations in androgens and prolactin. We had limited power to
assess reported oestrogen differences by smoking status (Bernstein
et al, 1989), thus the lower progesterone and prolactin concentra-
tions we observed among smokers may be noteworthy.
Birth weight, an established prenatal breast cancer risk factor
(Michels and Xue, 2006), is hypothesised to be mediated by foetal
oestrogen exposure (Michels et al, 1996). Third trimester maternal
oestriol is elevated in high birth weight pregnancies (Kaijser et al,
2000; Mucci et al, 2003; Peck et al, 2003; Troisi et al, 2003; Nagata
et al, 2006), but data for second trimester estrogens are conflicting
(Kaijser et al, 2000; Wuu et al, 2002). Our data show no association
of birth weight with first trimester estrogens seeming to suggest
that if oestrogen explains the association of birth weight and breast
cancer risk, the critical exposure window may be later in
pregnancy. Yet associations of birth weight with cord estrogens
are unclear (Simmons et al, 1994; Shibata et al, 2002; Troisi et al,
2003; Nagata et al, 2006), and breast cancer risk in women
prenatally exposed to diethylstilbestrol does not differ by trimester
of first exposure (Palmer et al, 2006). Other prenatal factors could
act differently. For example, a more pronounced breast cancer risk
is suggested for women who were in utero during the Dutch famine
in early compared with later gestation (Painter et al, 2006).
Long-term maternal breast cancer risk is reduced with a full-
term pregnancy, particularly when it occurs at a young age
(National Cancer Institute, 2003). Epidemiologic data indicate
protection increases with gestational length (Vatten et al, 2002),
suggesting that the important hormonal events must occur late in
Table 1 Spearman correlations between maternal hormone concentrations and maternal, gestational and neonatal characteristics (n¼420)
Androstenedione Testosterone DHEAS Estradiol Estrone Progesterone SHBG Prolactin
Gestational age
a  0.15**  0.15**  0.21*** 0.42*** 0.31*** 0.31*** 0.45*** 0.17***
Maternal age  0.30***  0.20***  0.34***  0.26***  0.19*** 0.09  0.03  0.17***
Maternal pregnancy weight
a 0.14** 0.31*** 0.14**  0.02  0.03  0.27***  0.27***  0.01
Maternal height 0.03 0.05 0.06  0.09  0.08 0.00  0.09  0.05
Maternal BMI
a 0.12** 0.30*** 0.12* 0.02 0.02  0.31***  0.25*** 0.02
Birth weight  0.01 0.02  0.01 0.05 0.04  0.02 0.01  0.06
*Po0.05; **Po0.01; ***Po0.001.
aAt blood draw (first prenatal visit).
Table 2 Results of linear regression models predicting maternal hormone concentrations
a
Percent change (P-value)
Independent
variables
Androstene-
dione
Testoste-
rone DHEAS Estradiol Estrone
Progeste-
rone SHBG Prolactin
Maternal age (years)  2% (o0.0001)  2% (0.0005)  3% (o0.0001)  2% (0.0001)  2% (0.01) 1% (0.12)
Nulliparous vs parous 19% (0.002) 23% (0.0008) 17% (0.002) 24% (0.003) 59% (o0.0001)
Maternal height (cm)  0.6% (0.04)  0.9% (0.04)  0.7% (0.0003)
Maternal BMI at initial
visit (kgm
 2)
1% (0.004) 3% (o0.0001) 2% (0.0004)  2% (o0.0001)  2% (o0.0001)
Current smoker
vs past/never
 21% (0.001)  19% (0.03)
Ever alcohol intake
vs never
 11% (0.02)
Education
(o13 vs 13+ years)
aEstimates are from regression models including all factors that were associated with the hormones in the categorical analyses and gestational age at blood collection and are
presented if they remained statistically significant or if they changed less than 10% in the full model. The estimates represent the percent increase or decrease in the hormone
concentration for each unit increase in the independent variable. Analyses excluded (n¼10) subjects with gestational lengths X14 weeks to restrict the findings to the first
trimester; n¼410.
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ypregnancy. However, protection from a full-term pregnancy would
also be consistent with cumulative dose effects of specific
hormones throughout the pregnancy, or early hormonal events
which require the subsequent action of others to induce the
relevant molecular changes. Descriptive data characterising the
hormonal profile of the entire pregnancy are lacking with regard to
parity. The elevated first trimester oestradiol we observed in first
compared with subsequent pregnancies has also been shown for
the second (Wuu et al, 2002; Arslan et al, 2006) and early third
trimesters (Wuu et al, 2002), but perhaps not at delivery (Troisi
et al, 2003). The elevated prolactin concentrations in our data for
first pregnancies have also been noted in the second trimester
(Xu et al, 2003; Arslan et al, 2006), but not later in the pregnancy
(Xu et al, 2003), and the first trimester androgen elevations have
not been shown at delivery (Troisi et al, 2003). Our data also
indicate that oestrogen and androgen concentrations are higher in
pregnancies that occur in younger than in older women. There is
limited and conflicting information for maternal estrogens by age
at any point during the pregnancy (Panagiotopoulou et al, 1990;
Kaijser et al, 2002; Troisi et al, 2003), whereas the androgen
findings are consistent with studies using measurements made
later in the pregnancy (Carlsen et al, 2003; Troisi et al, 2003).
The explanation for the protective effect of a first pregnancy and
the inverse relationship of this protection with the age at which the
pregnancy occurs remains speculative. The hypothesis most
commonly invoked is that irreversible molecular changes (driven
by hormonal exposures) to the breast that prevent tumour
initiation (Medina, 2005) must occur early in life to precede the
initial stage of breast carcinogenesis, and that most of these
changes occur with the first pregnancy. An alternative explanation,
however, is that the operative hormonal influences may be
different in first pregnancies, particularly those occurring at young
ages. Our finding of higher circulating estrogens, androgens and
prolactin in both a first pregnancy and, independently, in those
occurring at younger ages could be consistent with this latter
explanation. Subsequently reduced concentrations of these hor-
mones in the pregnant and non-pregnant state may also be
involved.
The study subjects were participants in a health care plan that
provides prenatal care. The MGH study’s participation rate is high
and thus unlikely to represent an unusual population of women
who seek medical care early in pregnancy. Whereas the
reproducibility data were high for oestradiol and oestrone, there
was substantial laboratory imprecision for other analytes that
based on the quality control data suggested sporadic, random
measurement errors. Finally, it is unknown how well a single first
trimester hormone measurement represents early pregnancy
exposure.
Our data suggest that birth weight is not a marker of early
pregnancy hormonal exposure, and that if hormones mediate any
of the birth weight and breast cancer association the effect is likely
to occur later in the pregnancy. Elevated first trimester oestrogen,
androgen and prolactin concentrations in first full-term pregnan-
cies, and elevated oestrogen, androgen and progesterone concen-
trations in pregnancies occurring at younger ages may be
consistent with these hormones acting to reduce later breast
cancer risk.
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